Sangamo Therapeutics, Inc.
SGMO
$0.14
$0.000.22%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -31.57% | -37.13% | 565.52% | 239.92% | -67.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -31.57% | -37.13% | 565.52% | 239.92% | -67.20% |
| Cost of Revenue | 0.13% | -25.40% | -38.67% | -50.65% | -51.70% |
| Gross Profit | -34.37% | 18.31% | 86.27% | 80.21% | 1.30% |
| SG&A Expenses | -22.00% | -23.03% | -28.76% | -19.89% | -25.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.21% | -24.79% | -36.29% | -44.22% | -46.29% |
| Operating Income | -8.71% | 19.99% | 71.65% | 66.61% | 14.04% |
| Income Before Tax | -25.88% | 18.91% | 74.45% | 76.11% | 62.68% |
| Income Tax Expenses | -240.12% | -3,583.33% | -116.50% | 97.17% | 96.71% |
| Earnings from Continuing Operations | -25.52% | 19.23% | 74.64% | 75.78% | 62.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.52% | 19.23% | 74.64% | 75.78% | 62.01% |
| EBIT | -8.71% | 19.99% | 71.65% | 66.61% | 14.04% |
| EBITDA | -10.42% | 19.75% | 72.48% | 66.78% | 6.13% |
| EPS Basic | 13.16% | 39.96% | 79.35% | 79.75% | 65.09% |
| Normalized Basic EPS | 16.72% | 38.10% | 76.26% | 71.63% | 15.06% |
| EPS Diluted | 14.76% | 39.74% | 78.68% | 79.25% | 64.61% |
| Normalized Diluted EPS | 17.03% | 38.26% | 76.10% | 71.49% | 15.01% |
| Average Basic Shares Outstanding | 39.41% | 28.75% | 21.20% | 18.79% | 15.07% |
| Average Diluted Shares Outstanding | 38.38% | 27.75% | 22.01% | 19.63% | 15.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |